SARS-CoV-2, the causative agent of COVID-19, has an ssRNA genome of almost 30kb that encodes for a total of 26 proteins. Among the four structural viral protein, in particular the S protein stands out. The S protein protrudes from the spherical virion and gives it its characteristic appearance. It is also crucial for the virus’ interaction with its host cells. Furthermore, the S protein is the main target for most SARS-CoV-2 vaccines. As such, mutations in this protein can severely impact the efficacy of SARS-CoV-2 vaccines.
In this webinar, Dr. Stefan Pellenz Product Manager from Antibodies online and Dr. Andreas Langer, R&D Scientist at NanoTemper Technologies, will review known SARS-CoV-2 S protein mutations, discuss their potential effect on antibody binding, and illustrate this effect on a well characterized anti-S protein antibody.
Learn more about the references mentioned in this webinar.
Ready to characterize your most challenging interactions?
Discover tools to measure binding affinity
See more related content
NanoTemper Technologies introduced Monolith X, adding breakthrough Spectral Shift technology to their top-selling Monolith product line.
2:20Introducing Monolith X - the only way to get binding affinities in solution using very minimal sample
NanoTemper’s Monolith wins top global design award: Red Dot Award
NanoTemper’s newest Monolith instrument has been awarded the Red Dot Award, an internationally recognized seal of excellence in design. Both bold aesthetics and user-friendly design have always...
10 terms to help you more easily understand targeted protein degradation
Targeted Protein Degradation (TPD), a relatively new therapeutic approach, is making waves by targeting otherwise ‘undruggable’ proteins. PROTACs are the best-understood protein degraders, with...
14:01The desire to use technology that allows you to study membrane proteins in close-to-native conditions is specifically important when it comes to interaction measurements. It’s always a question how mu
35:47Targeted protein degradation using molecular glues or proteolysis-targeting chimeras (PROTACs) is an increasingly important therapeutic modality, especially for undruggable targets. Even with candidat
Why so many companies are betting on PROTACs as a superior therapeutic modality
With PROTACs currently in the clinical and preclinical stages, they are making exciting progress towards successfully treating patients who have been waiting for effective therapies for certain...
MST and TRIC technology to reliably study PROTAC binary and ternary binding in drug development
27:20Explore the complexities and drivers of molecular interactions with Dr. Tom Laue from the University of New Hampshire. He presented as a keynote speaker in the Protein Stability & Function: Can't have
33:11Dr. Leah Pandiscia and Dr. Daniel Turman review how to integrate the Prometheus Panta and Monolith instruments in a characterization workflow demonstration, showing how to maximize stability and funct
NanoTemper’s Monolith wins top global design award: iF DESIGN AWARD 2021
NanoTemper’s newest Monolith instrument has been awarded the globally renowned iF DESIGN AWARD 2021. User-friendly design has always been a core focus in NanoTemper’s product development....
25:40Are you struggling to tame your mischievous membrane proteins? Find out how NanoTemper can help you to characterize even the most challenging membrane protein samples. You will learn how Prometheus ca
Targeted protein degradation promises to lead the way to effective drugs for challenging targets
Quantifying the interaction of phosphite with ABC transporters: MicroScale Thermophoresis and a novel his-tag labeling approach